SCHEMBL25258342

SCHEMBL25258342

Cc1cn(COCC[Si](C)(C)C)c(S(=N)(=O)c2ccc(C(=O)O)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 8/20 0.37
▸ KLKB1 P03952 1/20 0.36
▸ RARB P10826 3/20 0.35
▸ RARA P10276 1/20 0.35
▸ RARG P13631 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25254344 0.91 KDM4E (0.39) DGAT1MEN1KMT2AKDM4EALDH1A1
SCHEMBL25247355 0.83 KLKB1 (0.36) DGAT1KLKB1RARBRARARARG
SCHEMBL25214568 0.82 DGAT1 (0.36) DGAT1KLKB1RARBRARARARG
SCHEMBL25215381 0.80 DGAT1 (0.34) DGAT1KLKB1MEN1KMT2AKDM4E
SCHEMBL25268981 0.79 DGAT1 (0.34) DGAT1KLKB1RARBRARARARG
SCHEMBL25211606 0.79 NPC1 (0.36) DGAT1RARBRARARARGMEN1
SCHEMBL25215427 0.78 MEN1 (0.33) DGAT1KLKB1MEN1KMT2AALDH1A1
SCHEMBL25213344 0.76 TBXAS1 (0.34) RARBMEN1KMT2ANPC1
SCHEMBL25223336 0.76 PSMD10 (0.39) DGAT1KMT2AKDM4EALDH1A1NPC1
SCHEMBL25254364 0.75 NPC1 (0.36) DGAT1RARBRARARARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 DGAT1 1440/4885KLKB1 2165/4885RARB 653/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 DGAT1 1931/4885KLKB1 2006/4885RARB 807/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 DGAT1 1931/4885KLKB1 2006/4885RARB 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback